SOMMAIRE :
- New psychoactive substances: Challenges of sharing analytical data and knowledge in a European regulatory context [Editorial]. Guillou C., p. 1-2.
- Chernobyl syndrome? [Editorial]. Gaulier J.-M., p. 3.
- Interpretation of NPS results in real hair samples. Salomone A., Vincenti M., Gerace E., p. 4-10.
- Challenges concerning new psychoactive substance detection in oral fluid. Wille S.M.R., Eliaerts J., Di Fazio V., Samyn N., p. 11-17.
- A 6-year review of new psychoactive substances at the Centre antipoison Grand-Ouest d'Angers: Clinical and biological data. Turcant A., Deguigne M., Ferec S., Bruneau C., Leborgne I., Lelievre B., et al., p. 18-33.
- Poisoning by synthetic cathinones: Consumption behaviour and clinical description from 11 cases recorded by the Addictovigilance Centre of Bordeaux. Daveluy A., Labadie M., Titier K., Courtois A., Penouil F., Castaing N., et al., p. 34-40.
- New psychoactive substances in a drugged driving population: Preliminary results. Nachon-Phanithavong M., Wille S., Richeval C., Di Fazio V., Samyn N., Humbert L., et al., p. 41-46.
- CHEMSEX, NPS & risk reduction management: Preliminary results of a pilot study. Marillier M., Batisse A., Richeval C., Labrouve V., Martinez M., Allorge D., et al., p. 47-56.
- Characterization of metizolam, a designer benzodiazepine, in alternative biological specimens. Kintz P., Jamey C., Ameline A., Richeval C., Raul J.-S., p. 57-63.
- Identification and quantification of diphenidine in hair by LC-MS/MS after single administration. Alvarez J.-C., Fabresse N., Knapp A., El Hajj Sleiman I., Garnier R., Langrand J., p. 64-70.
- Retrospective identification of 25I-NBOMe metabolites in an intoxication case. Richeval C., Boucher A., Humbert L., Phanithavong M., Wiart J.-F., Moulsma M., et al., p. 71-81.
- 2,5-dimethoxy-4-chloroamphetamine, a LSD-like designer drug: Clinical and analytical documentation of non-fatal exposure in five patients. Abbara C., Ferec S., Leroux G., Bretaudeau-Deguigne M., Lelievre B., Boels D., et al., p. 82-89.
- The development of new psychoactive substances in France. Roussel O., Tensorer L., Bouvot X., Balter C., Sabini S., Carlin M.G., p. 90-95.
- "NRG-3": What's in this? Batisse A., Marillier M., Chevallier C., Bourgogne E., Grégoire M., Laprévote O., et al., p. 96-100.
- Case reports: Four concomitant non-fatal intoxications with AB-FUBINACA and MDMA. Allibe N., Richeval C., Willeman T., Humbert L., Allorge D., Maignan M., et al., p. 101-110.
- Madness with five dollars: Two new cases of non-lethal poisoning flakka (alpha-PVP). Dumestre-Toulet V., Brault S., Labadie M., Penouil-Pucheu F., p. 111-116.
- Identification of 25I-NBOMe in two intoxications cases with severe hallucinations. Ameline A., Kintz P., Blettner C., Bayle É., Raul J.-S., p. 117-122.
- A fatal case of 3-methylmethcathinone (3-MMC) poisoning. Bottinelli C., Cartiser N., Gaillard Y., Boyer B., Bévalot F., p. 123-129.
- Presence of mephedrone and methylone in an attempted suicide: A surprising result where toxicological analyses have changed the initial conclusions. Aknouche F., Guibert E., Tessier A., Kintz P., p. 130-133.
- "Synthacaines": A mosaic of substances for a wide range of effects, from a case. Deslandes G., Monteil-Ganière C., Grégoire M., Allard S., Marion M., Bouquié R., p. 134-138.
- LSD instead of 25I-NBOMe: The revival of LSD? A case report. Bodeau S., Bennis Y., Régnaut O., Fabresse N., Richeval C., Humbert L., et al., p. 139-143.
- The comeback of Ecstasy: New designs and increased MDMA content. Richeval C., Humbert L., Néfau T., Martinez M., Allorge D., Gaulier J.-M., p. 144-145.